Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Volume 73, Number 3, July 21, 2009
Right arrow Podcast
Right arrow Japanese Translation
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Rajput, A. H.
Right arrow Articles by Rajput, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajput, A. H.
Right arrow Articles by Rajput, A.
NEUROLOGY 2009;73:206-212
© 2009 American Academy of Neurology

Course in Parkinson disease subtypes

A 39-year clinicopathologic study

A. H. Rajput, FRCPC, A. Voll, M. L. Rajput, PhD, C. A. Robinson, FRCPC and A. Rajput, FRCPC

From the Division of Neurology (A.H.R., M.L.R., A.R.), Parkinson’s Disease and Movement Disorder Program, University of Saskatchewan/Saskatoon Health Region; College of Medicine (A.V.), University of Saskatchewan; and Division of Neuropathology (C.A.R.), Department of Pathology, Saskatoon Health Region/University of Saskatchewan, Canada.

Address correspondence and reprint requests to Dr. Ali H. Rajput, Room 1663, Royal University Hospital, Saskatoon, Saskatchewan S7N 0W8, Canada ali.rajput{at}saskatoonhealthregion.ca

Background: Individual variations in the course of Lewy body Parkinson disease (PD) are well known. Patients have been classified into different clinical subtypes to identify differences in the course among the subgroups. Several studies indicate that the outcome is more favorable in tremor dominant (TD) cases but others report no difference. A majority of progression studies are based on cross-sectional single point data or short-term clinical observations. The lack of longitudinally followed autopsy-confirmed PD cohort remains a major weakness in the literature. Biochemical studies of brain indicate most pronounced abnormalities in akinetic/rigid (AR) and the least in TD cases. We postulate that PD course in these subtypes is concordant with the biochemical findings.

Objective: To compare the course in TD, mixed (MX), and AR subtypes of PD.

Methods: Longitudinal clinical follow-up and autopsy studies were performed on 166 patients with PD over 39 years (1968–2006). Patients were classified into TD, AR, and MX based on the entire clinical course. Only the pathologically confirmed PD cases were included.

Results: Sixty-six percent of cases had MX, 26% AR, and 8% TD profile. The age at onset was younger (p < 0.001) and progression to Hoehn & Yahr stage 4 was slower (p = 0.016) in the TD cases. Dementia was most common in AR (p = 0.039) and the least common in TD. In general, the course was most favorable in TD, followed by MX and AR subgroups.

Conclusion: The three subtypes of Parkinson disease have different courses which are concordant with the differences in brain biochemical abnormalities.

Abbreviations: AR = akinetic/rigid; CBG = corticobasal ganglia degeneration; ET = essential tremor; H&Y = Hoehn & Yahr; LB = Lewy body; LD = levodopa; MDCS = Movement Disorder Clinic Saskatoon; MSA = multiple system atrophy; MX = mixed; PD = Parkinson disease; PIGD = postural instability and gait difficulty dominant; PSP = progressive supranuclear palsy; SN = substantia nigra; TD = tremor dominant; UPDRS = Unified Parkinson’s Disease Rating Scale.


Disclosure: Author disclosures are provided at the end of the article.

Received October 24, 2008. Accepted in final form April 6, 2009.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by AAN Enterprises, Inc.